Related Experiment Video
Updated: Jun 21, 2026
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
Treatment of venous thromboembolism: guidelines translated for the clinician
M Houman Fekrazad1, Renato D Lopes, Gregg J Stashenko
1Division of Hematology/Oncology, University of New Mexico, Albuquerque, NM, USA.
Insights
This summary outlines the latest American College of Chest Physicians guidelines for treating venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). It provides practical applications for initial anticoagulant therapies, duration, and advanced treatments.
Area of Science:
- Cardiology
- Hematology
- Internal Medicine
Background:
- Venous thromboembolism (VTE) is a significant cause of illness and death, impacting millions annually.
- The American College of Chest Physicians (ACCP) has established guidelines for antithrombotic therapy since 1986, with the latest in 2008.
- Practicing physicians require updated guidance for managing VTE effectively.
Purpose of the Study:
- To summarize the most recent ACCP guidelines on venous thromboembolism therapy.
- To provide practical applications and interpretations for physicians.
- To review evidence and recommendation strengths used in the guidelines.
Main Methods:
- Review of the 2008 ACCP guidelines on antithrombotic therapy.
- Discussion of initial anticoagulant options: low molecular weight heparin, unfractionated heparin, and fondaparinux.
- Analysis of guidelines on anticoagulant duration, thrombolytic therapy, IVC filters, and postphlebitic syndrome prevention.
Main Results:
- Recommendations for initial anticoagulant treatments for deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Guidance on the duration of anticoagulant therapy using vitamin K antagonists.
- Considerations for thrombolytic therapy, inferior vena cava (IVC) filters, and prevention of postphlebitic syndrome.
Conclusions:
- The summary provides a practical approach to applying the 2008 ACCP guidelines for VTE management.
- It covers initial treatment, duration, and adjunctive therapies like thrombolysis and IVC filters.
- Future directions, including novel anticoagulants, are briefly discussed.
Abstract:
Venous thromboembolism is a major cause of morbidity and mortality affecting over 2 million people in the United States each year. The American College of Chest Physicians (ACCP) published their first consensus statement on antithrombotic therapy in 1986, and the most recent guidelines from the ACCP on this topic were released in 2008. We aim to summarize the most recent ACCP guidelines on therapy for venous thromboembolism with practical application and interpretation for the practicing physician. We will briefly review the rating system used in the guidelines for the level of evidence and the strength of the recommendation. We will then discuss the recommendations for initial anticoagulant therapies including low molecular weight heparin, unfractionated heparin, and fondaparinux for patients with both deep vein thrombosis (DVT) and pulmonary embolism (PE). A discussion of the guidelines on duration of anticoagulant therapy with a vitamin K antagonist is also included. In addition, we will address the use of thrombolytic therapy and inferior vena cava filter placement for DVT and PE. Prevention of postphlebitic syndrome is discussed as well. We will conclude with a brief discussion of future directions including several novel therapeutic anticoagulants.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Venous Thrombosis IV: Nursing Management
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:27Pulmonary Embolism III: Nursing Management
01:30Venous Thrombosis I: Introduction
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care